X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (81) 81
humans (75) 75
diabetes mellitus, type 2 - drug therapy (65) 65
sitagliptin (60) 60
male (59) 59
female (55) 55
middle aged (51) 51
sitagliptin phosphate (47) 47
hypoglycemic agents - therapeutic use (46) 46
type 2 diabetes (46) 46
dipeptidyl-peptidase iv inhibitors - therapeutic use (34) 34
aged (32) 32
diabetes (32) 32
adult (31) 31
sitagliptin phosphate - therapeutic use (31) 31
drug therapy, combination (27) 27
endocrinology & metabolism (27) 27
hypoglycemic agents - economics (27) 27
pyrazines - therapeutic use (26) 26
triazoles - therapeutic use (26) 26
metformin (24) 24
pharmacology & pharmacy (24) 24
hypoglycemic agents (23) 23
hypoglycemic agents - administration & dosage (23) 23
treatment outcome (23) 23
analysis (21) 21
glycemic control (21) 21
diabetes mellitus, type 2 - blood (20) 20
cost-benefit analysis (18) 18
dipeptidyl peptidase-4 inhibitor (18) 18
hypoglycemic agents - adverse effects (18) 18
diabetes therapy (17) 17
efficacy (16) 16
diabetes mellitus, type 2 - economics (15) 15
dipeptidyl-peptidase iv inhibitors - economics (15) 15
glycated hemoglobin a - metabolism (15) 15
mellitus (15) 15
cohort studies (14) 14
dipeptidyl-peptidase iv inhibitors - pharmacology (14) 14
insulin (14) 14
metformin - therapeutic use (14) 14
pyrazines - pharmacology (14) 14
triazoles - pharmacology (14) 14
blood glucose - drug effects (13) 13
hypoglycemic agents - pharmacology (13) 13
liraglutide (13) 13
pyrazines - economics (13) 13
retrospective studies (13) 13
safety (13) 13
sitagliptin phosphate - economics (13) 13
triazoles - economics (13) 13
adamantane - analogs & derivatives (12) 12
adamantane - therapeutic use (12) 12
animals (12) 12
clinical trials (12) 12
diabetes mellitus, type 2 - complications (12) 12
glucagon-like peptide 1 - analogs & derivatives (12) 12
internal medicine (12) 12
medicine, general & internal (12) 12
research (12) 12
sitagliptin phosphate - adverse effects (12) 12
blood glucose - metabolism (11) 11
body weight (11) 11
diabetes mellitus (11) 11
drug therapy (11) 11
glucagon-like peptide-1 (11) 11
pyrazines - administration & dosage (11) 11
sitagliptin phosphate - administration & dosage (11) 11
triazoles - administration & dosage (11) 11
type 2 diabetes mellitus (11) 11
glucose (10) 10
glycated hemoglobin a - analysis (10) 10
glycosylated hemoglobin (10) 10
medicine, research & experimental (10) 10
metformin - administration & dosage (10) 10
peptides - therapeutic use (10) 10
venoms - therapeutic use (10) 10
beta-cell function (9) 9
body mass index (9) 9
care and treatment (9) 9
complications (9) 9
dosage and administration (9) 9
glycated hemoglobin a - drug effects (9) 9
hypoglycemia (9) 9
sulfonylurea (9) 9
united states (9) 9
cost-effectiveness (8) 8
dipeptides - therapeutic use (8) 8
dipeptidyl-peptidase iv inhibitors - administration & dosage (8) 8
health care sciences & services (8) 8
insulin glargine (8) 8
medicine & public health (8) 8
peptides - economics (8) 8
randomized controlled trials as topic (8) 8
type-2 diabetes-mellitus (8) 8
venoms - economics (8) 8
association (7) 7
canagliflozin - therapeutic use (7) 7
comparative analysis (7) 7
dipeptidyl-peptidase iv inhibitors - adverse effects (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetic Medicine, ISSN 0742-3071, 04/2016, Volume 33, Issue 4, pp. 471 - 477
The study is unique in reporting resource use associated with severe hypoglycaemia from a randomized controlled trial setting, because resource use has... 
GLYCEMIC CONTROL | 26-WEEK | GLARGINE | NAIVE PATIENTS | ENDOCRINOLOGY & METABOLISM | NON-INFERIORITY TRIAL | OPEN-LABEL | TO-TARGET TRIAL | BASAL-BOLUS TREATMENT | TYPE-2 | DEGLUDEC/INSULIN ASPART | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Insulin Detemir - therapeutic use | Insulin Detemir - economics | Clinical Trials, Phase III as Topic | Hypoglycemic Agents - administration & dosage | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Costs and Cost Analysis | Administration, Oral | Drug Therapy, Combination - economics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Insulin Aspart - economics | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Diabetes Mellitus, Type 1 - economics | Diabetes Mellitus, Type 1 - blood | Insulin, Long-Acting - therapeutic use | Hypoglycemic Agents - adverse effects | Insulin Aspart - adverse effects | Cohort Studies | Insulin Aspart - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diabetes Mellitus, Type 2 - economics | Insulin, Long-Acting - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Insulin Aspart - administration & dosage | Insulin Detemir - administration & dosage | Insulin Detemir - adverse effects | Hypoglycemia - physiopathology | Adult | Hypoglycemia - economics | Hypoglycemia - chemically induced | Severity of Illness Index | Insulin Glargine - adverse effects | Drug Administration Schedule | Insulin Glargine - economics | Insulin Glargine - therapeutic use | Sitagliptin Phosphate - economics | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Health Care Costs | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Combinations | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Adults | Type 1 diabetes | Insulin | Analysis | Emergency medical care | Diabetes | Hypoglycemia | Index Medicus | Complications | Research
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 1921 - 1927
Aims The recent LIRA-SWITCH trial showed that switching from sitagliptin 100 mg to liraglutide 1.8 mg led to statistically significant and clinically relevant... 
cost‐effectiveness | GLP‐1 analogue | type 2 diabetes | incretin therapy | liraglutide, sitagliptin | cost-effectiveness | GLP-1 analogue | liraglutide | VALIDATION | UTILITY VALUES | MELLITUS | MODEL | sitagliptin | DISEASE | ENDOCRINOLOGY & METABOLISM | MULTIFACTORIAL INTERVENTION | COMPLICATIONS | OUTCOMES | Anti-Obesity Agents - economics | Hypoglycemia - therapy | Overweight - complications | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Overweight - drug therapy | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Anti-Obesity Agents - adverse effects | Diabetes Mellitus, Type 2 - economics | Diabetes Complications - therapy | Diabetes Mellitus, Type 2 - metabolism | Models, Economic | Weight Loss - drug effects | Anti-Obesity Agents - therapeutic use | Liraglutide - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Hypoglycemia - prevention & control | Overweight - metabolism | Glucagon-Like Peptide-1 Receptor - metabolism | Diabetes Complications - epidemiology | Hypoglycemia - economics | Hypoglycemia - chemically induced | Overweight - economics | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Diabetes Complications - prevention & control | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Hyperglycemia - economics | Risk Factors | Sitagliptin Phosphate - economics | Diabetes Complications - economics | Health Care Costs | Liraglutide - adverse effects | Cost-Benefit Analysis | Liraglutide - therapeutic use | Quality of Life | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Hyperglycemia - therapy | Hypoglycemic Agents - adverse effects | United Kingdom - epidemiology | Glucagon-Like Peptide-1 Receptor - agonists | Cohort Studies | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Hypoglycemic agents | Cost benefit analysis | Health aspects | Analysis | Body mass index | Costs | Statistical analysis | Life span | Diabetes mellitus | Hemoglobin | Diabetes | Diabetes mellitus (non-insulin dependent) | Patients | Clinical outcomes | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2018, Volume 20, Issue 7, pp. 1732 - 1739
Aims: TECOS, a cardiovascular safety trial (identifier: NCT00790205) involving 14 671 patients with type 2 diabetes and cardiovascular disease, demonstrated... 
costs | sitagliptin | dipeptidyl peptidase‐4 inhibitor | cost analysis | diabetes | dipeptidyl peptidase-4 inhibitor | MORTALITY | GLUCOSE | DISEASE | ENDOCRINOLOGY & METABOLISM | RISK | DEATH | MELLITUS | Hypoglycemic Agents - economics | Length of Stay - economics | United States | Humans | Middle Aged | Hospitalization - statistics & numerical data | Diabetes Mellitus, Type 2 - economics | Male | Health Resources - statistics & numerical data | Drug Costs - statistics & numerical data | Female | Equivalence Trials as Topic | Length of Stay - statistics & numerical data | Hypoglycemic Agents - therapeutic use | Proportional Hazards Models | Health Resources - economics | Linear Models | Sitagliptin Phosphate - economics | Randomized Controlled Trials as Topic | Cost-Benefit Analysis | Health Care Costs - statistics & numerical data | Sitagliptin Phosphate - therapeutic use | Aged | Ambulatory Care - economics | Ambulatory Care - statistics & numerical data | Diabetes Mellitus, Type 2 - drug therapy | Longitudinal Studies | Hospitalization - economics | Type 2 diabetes | Hypoglycemic agents | Valuation | Medical economics | Analysis | Patient outcomes | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Patients | Diabetes mellitus | Generalized linear models | Index Medicus | Clinical Medicine | costs; cost analysis; diabetes; dipeptidyl peptidase-4 inhibitor; sitagliptin | Medical and Health Sciences | Endokrinologi och diabetes | Medicin och hälsovetenskap | Klinisk medicin | Endocrinology and Diabetes
Journal Article
Primary Care Diabetes, ISSN 1751-9918, 2015, Volume 10, Issue 3, pp. 220 - 226
Highlights • Cost–benefit analysis to compare liraglutide vs. sitagliptin for the control of T2DM in Italy. • The cost of control is lower for liraglutide at... 
Internal Medicine | Endocrinology & Metabolism | T2DM | Liraglutide | Cost control | Cost–benefit analysis | Cost-benefit analysis | INSULIN | THERAPY | INITIATION | ENDOCRINOLOGY & METABOLISM | PRIMARY HEALTH CARE | Drug Costs | Meta-Analysis as Topic | Metformin - therapeutic use | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Diabetes Mellitus, Type 2 - economics | Models, Economic | Liraglutide - economics | Metformin - adverse effects | Cost Savings | Dipeptidyl-Peptidase IV Inhibitors - economics | Metformin - economics | Time Factors | Drug Therapy, Combination | Hypoglycemic Agents - therapeutic use | Drug Substitution - economics | National Health Programs - economics | Treatment Outcome | Biomarkers - blood | Sitagliptin Phosphate - economics | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - diagnosis | Diabetes Mellitus, Type 2 - blood | Liraglutide - adverse effects | Cost-Benefit Analysis | Liraglutide - therapeutic use | Sitagliptin Phosphate - therapeutic use | Italy | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Care and treatment | Analysis | Clinical trials | Sitagliptin | Dosage and administration | Comparative analysis | Index Medicus
Journal Article
Primary Care Diabetes, ISSN 1751-9918, 2014, Volume 9, Issue 5, pp. 370 - 376
Highlights • BIAsp 30 therapy after sitagliptin failure is effective and well tolerated. • Different outcomes using 3 distinct intensification regimens with... 
Internal Medicine | Endocrinology & Metabolism | Type 2 diabetes | Sitagliptin | Randomized trial | Biphasic insulin | MONOTHERAPY | EFFICACY | SAFETY | ENDOCRINOLOGY & METABOLISM | OPEN-LABEL | PRIMARY HEALTH CARE | MELLITUS | COMBINATION | Drug Costs | South America | Hypoglycemic Agents - economics | Biphasic Insulins - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Diabetes Mellitus, Type 2 - economics | Insulin, Isophane - economics | Male | Metformin - adverse effects | Metformin - economics | Insulin Aspart - administration & dosage | Hypoglycemic Agents - administration & dosage | Time Factors | Female | Metformin - administration & dosage | Drug Therapy, Combination | Insulin, Isophane - administration & dosage | Sitagliptin Phosphate - administration & dosage | Drug Administration Schedule | Europe | Treatment Outcome | Biomarkers - blood | Sitagliptin Phosphate - economics | Insulin Aspart - economics | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - diagnosis | Diabetes Mellitus, Type 2 - blood | Asia | Cost-Benefit Analysis | Biphasic Insulins - economics | Insulin, Isophane - adverse effects | Aged | Biphasic Insulins - administration & dosage | Australia | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin Aspart - adverse effects | Sitagliptin Phosphate - adverse effects | Index Medicus
Journal Article
Advances in Therapy, ISSN 0741-238X, 1/2016, Volume 33, Issue 1, pp. 68 - 81
Journal Article
Journal of Medical Economics, ISSN 1369-6998, 07/2016, Volume 19, Issue 7, pp. 672 - 683
Journal Article
Journal Article
Journal Article
Enzyme and Microbial Technology, ISSN 0141-0229, 11/2019, Volume 130, pp. 109362 - 109362
Transaminases (TAs, EC 2.6.1.X) are a class of promising catalysts for the synthesis of chiral amines. The addition of exogenous expensive cofactor, pyridoxal... 
Sitagliptin | Pyridoxal 5′-phosphate | Co-immobilization | Continuous biosynthesis | Transaminase | Self-sufficient biocatalyst | Index Medicus
Journal Article